RxDoctor Payments Data

Daniel Anderson, MD

Family Medicine · North Mankato, MNNPI 1356320675

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $243 of the $275 with a category attached, or 88.5%. It is spread thinly across 13 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations.

$275in general payments, 2019–2025

Across 16 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$49
  • Amgen$30
  • Harmony Biosciences LLC$28
  • Pfizer$28
  • Ironshore Pharmaceuticals Inc.$24
  • Aimmune Therapeutics, Inc.$22
  • plus $94 from 7 others
$33,170in research payments, 2019–2025

Across 2 payments — averaging $16,585 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$33K

What the payments were for

  • Food & beverage$24389%
  • Education$3211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$275 in reported general payments places this provider in the 85th percentile of 1,162 family medicine providers in Minnesota.

See all family medicine providers in Minnesota

Medicare billing

Part B allowed, 2024
$243,401
Medicare patients
446
Services billed
8,787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide46$94,599
EliquisApixaban61$70,511
XareltoRivaroxaban53$69,911
OzempicSemaglutide31$48,251
JardianceEmpagliflozin19$33,429
MyrbetriqMirabegron24$23,781
Breo ElliptaFluticasone/Vilanterol14$15,868
Humalog Kwikpen U-100Insulin Lispro16$14,446
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate29$12,614
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$9,801
Atorvastatin Calcium668$6,906
SymbicortBudesonide/Formoterol Fumarate12$6,427
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,969
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$4,772
Omeprazole323$4,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$28$71,96781 claims
Johnson & JohnsonXarelto$13$69,91153 claims
Novo NordiskOzempic$11$48,25131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,162 family medicine providers in Minnesota.

Other family medicine in North Mankato

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →